Pharmacoeconomics of key importance in formulary decision-making

Abstract

P harmacy & Therapeutic committees should supplement comparative clinical assessments with the results of pharmacoeconomic trials - this is of key importance in the decision-making process. But very few formulary committees are equipped to undertake pharmacoeconomic assessments on their own behalf, despite the increasing pressure to do so. Dr Paul Langley, Associate Director at the Center for Pharmaceutical Economics at the University of Arizona, outlined how a formulary committee could establish and maintain an economic evaluation unit at the Third Annual Pharmacoeconomic Conference [ Arizona, US; January 1995 ].